Pharmacokinetics of linezolid in subjects with renal dysfunction and ones under dialysis; an open-label,non-randomized study

Pharmacokinetics of linezolid in subjects with renal dysfunction and ones under dialysis; an open-label,non-randomized study - Pharmacokinetics of linezolid in subjects with renal dysfunction and under dialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004321

Enrollment

Registered

2010-10-04

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRSA infection

Interventions

Subjects are recruited into 4 groups on the basis of their estimated GFR. All patients received a dose of 600 mg linezolid every 12h intravenously. To investigate the pharmacokinetics of linezolid, bl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) age, 20 years or higher 2) MRSA infections, including suspicions 3) inpatients at intensive care unit 4) prescribed blood sampling were available 5) gave their or their relatives' written informed consent

Exclusion criteria

Exclusion criteria: 1) history of hypersensitivity to ZYVOX 2) pregnancy, parturition or lactation 3) other situation that doctor decides 4) switch to orally administration of linezolid

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameters of linezolid in subjects with renal dysfunction and ones under dialysis	—

Secondary

Measure	Time frame
Blood concentration-time profile of linezolid and major metabolites, and those of urinary extraction amounts in patients, the efficacy and safety of linezolid in patients with renal dysfunction, including patients receiving renal replacement therapy	—

Countries

Japan

Contacts

Public ContactYoshimichi Sai

Kanazawa University Hospital Department of Pharmacy

sai-ys@staff.kanazawa-u.ac.jp076-265-2046

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026